New Psoriasis Treatment: Oral Drug Approved for Plaque Psoriasis

A new treatment option is emerging for individuals managing plaque psoriasis, a common skin condition affecting millions. The U.S. Food and Drug Administration (FDA) has recently approved the first oral targeted therapy for moderate-to-severe plaque psoriasis in adults and adolescents aged 12 years and older, weighing at least 40 kg. This offers a new approach for those who haven’t found sufficient relief with existing treatments, particularly injectable biologics.

Understanding Plaque Psoriasis and Its Impact

Plaque psoriasis, the most prevalent form of the disease, accounts for approximately 80-90% of all psoriasis cases. It’s a chronic autoimmune inflammatory condition characterized by accelerated skin cell growth. Normally, skin cells regenerate over a period of 28-30 days, but in psoriasis, this process occurs in just 3-4 days. This rapid turnover leads to the formation of thickened, raised, red patches of skin covered with silvery-white scales, often accompanied by itching, burning and discomfort.

The condition affects men and women equally, typically appearing between the ages of 15 and 30, although it can develop at any age. Although the exact causes of psoriasis remain unknown, it’s understood to be linked to the immune system and a genetic predisposition. Stress is too recognized as a significant factor in triggering or exacerbating psoriasis flare-ups.

Romania has a particularly high prevalence of psoriasis in Europe, with an estimated 400,000 people affected. A concerning 20-30% of these individuals also develop psoriatic arthritis, a condition that can lead to severe and debilitating joint damage. Statistics highlight the substantial health burden of this disease within the country.

How Icotrokinra Works: Targeting the IL-23 Pathway

The newly approved medication, icotrokinra, represents a novel approach to psoriasis treatment. It’s an oral peptide that specifically targets and blocks the interleukin-23 (IL-23) receptor. IL-23 is a key pathway involved in the inflammatory processes driving psoriasis. By interrupting this pathway, icotrokinra aims to reduce the inflammation and subsequent skin symptoms.

This approval marks the first oral treatment in a new therapeutic class focused on the IL-23 receptor, expanding the systemic treatment options available for moderate-to-severe plaque psoriasis. The treatment is developed by Johnson & Johnson.

Clinical Trial Evidence: ICONIC Program Results

The FDA’s authorization is based on data from the Phase 3 ICONIC clinical trial program, which involved multiple studies with adults and adolescents (aged 12 years and older) experiencing moderate-to-severe plaque psoriasis. These studies assessed the efficacy and safety of icotrokinra compared to a placebo.

The trials demonstrated that the medication met its primary efficacy endpoints, showing significant improvements in skin lesion severity. Importantly, the drug also showed effectiveness in hard-to-treat areas like the scalp and genital region, as evaluated during the clinical studies. The safety profile of icotrokinra was found to be comparable to that of a placebo.

A Convenient Oral Alternative to Injections

Currently, many systemic psoriasis treatments require injection, which can be a barrier for some patients. Icotrokinra, administered as a once-daily tablet, offers a more convenient alternative. This oral formulation could improve adherence to treatment and enhance the overall patient experience.

What Does This Mean for Patients?

The availability of an oral targeted therapy provides a valuable new option for individuals with moderate-to-severe plaque psoriasis who haven’t responded adequately to other treatments. It’s important to remember that psoriasis management is often individualized, and the best treatment approach will vary depending on the severity of the condition, individual patient characteristics, and other factors. Patients should discuss the potential benefits and risks of icotrokinra with their dermatologist to determine if it’s an appropriate option for them.

Further research, including long-term studies, will be crucial to fully understand the long-term efficacy and safety of icotrokinra. The European Medicines Agency (EMA) provides detailed information on Skyrizi (risankizumab), another treatment for psoriasis, including administration details and potential side effects. Learn more about Skyrizi here.

Looking Ahead: Ongoing Research and Monitoring

The approval of icotrokinra is a significant step forward in psoriasis treatment, but ongoing research and monitoring are essential. The FDA will continue to monitor the safety and effectiveness of the drug through post-market surveillance. Researchers are exploring other potential targets and therapies for psoriasis, aiming to develop even more effective and personalized treatment strategies. The National Agency of Medicines and Medical Devices (ANM) in Romania also plays a role in evaluating and monitoring the safety and efficacy of medications available in the country. More information on medication evaluation can be found here.

For individuals living with psoriasis, staying informed about the latest treatment advances and working closely with a qualified healthcare professional are key to managing the condition and improving quality of life. If you are experiencing symptoms of psoriasis, it’s important to consult with a dermatologist for an accurate diagnosis and personalized treatment plan.